All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
On 11 February 2019, Ian Flinn from Sarah Cannon Research Institute, Nashville, TN, USA, and colleagues, published in the Journal of Clinical Oncology the results of the phase II trial DYNAMO. patients.
Duvelisib has been approved by the Food and Drug Administration (FDA) for relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and R/R follicular lymphoma (FL) patients, after two or more prior lines. In this open-label, global, phase II trial (NCT01882803) the efficacy and safety of single-agent, oral duvelisib were assessed in patients with R/R indolent non-Hodgkin lymphoma (iNHL). The primary endpoint of this study was overall response rate (ORR) assessed by an Independent Review Committee (IRC) according to the International Working Group (IWG) criteria for malignant lymphoma. Secondary endpoints, included progression-free survival (PFS), and safety.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox